Jatenzo Pediatric (Under 12): Caregiver Administration Guidance

Why Jatenzo Is Not FDA-Approved for Children Under 12

Jatenzo has no approved pediatric indication for patients under 12. The FDA-approved prescribing information specifies adult male use only, and the black-box warning highlights the risk of pulmonary oil microembolism (POME) and anaphylaxis after intramuscular testosterone injections. Although Jatenzo is oral, those warnings carry into all testosterone formulations reviewed under REMS programs. [1]

The FDA's current labeling for Jatenzo was reviewed under NDA 208088 and explicitly states that safety and efficacy in pediatric patients have not been established. [1] Any caregiver whose child has been prescribed Jatenzo under age 12 should confirm the clinical rationale with a board-certified pediatric endocrinologist before giving a single dose. [2]

Why a Prescriber Might Order It Anyway

Rare conditions such as congenital anorchia, Klinefelter syndrome with early endocrine failure, or severe hypogonadism from prior chemotherapy can prompt off-label androgen replacement before the approved age window. The Pediatric Endocrine Society notes that testosterone replacement in prepubertal and early-pubertal males must be "individually tailored to minimize bone-age advancement while supporting growth." [3]

Oral testosterone undecanoate is absorbed via the intestinal lymphatic pathway, which bypasses first-pass hepatic metabolism. This makes it a preferred oral option over older 17-alpha-alkylated androgens that carry hepatotoxicity risk. [4] Still, lymphatic absorption is highly meal-dependent, and that dependency creates real caregiver administration challenges in young children.

What the Research Gap Means for Caregivers

No published randomized controlled trial has evaluated Jatenzo specifically in children under 12. The key JATENZO trial (N=166 hypogonadal adult males) achieved average steady-state testosterone of 489 ng/dL with 237 to 396 mg twice-daily dosing, but enrolled no pediatric subjects. [5] Caregivers are therefore operating in a space where published pharmacokinetic data must be extrapolated from adult studies and from limited case series of oral testosterone undecanoate in adolescent males. [6]

FDA Black-Box Warning: What Caregivers Must Understand

The Jatenzo prescribing information contains two boxed warnings that apply regardless of age. Caregivers must read both before administering a single capsule. [1]

Blood Pressure Elevation Warning

In the key JATENZO clinical trial, 5.4% of adult subjects required new or increased antihypertensive therapy during the study period. Mean systolic blood pressure rose by 3.7 mmHg and mean diastolic BP by 2.9 mmHg. [5] In a child under 12, whose baseline BP and cardiovascular reserve differ from adults, even small absolute BP changes may cross age-specific hypertension thresholds defined by the American Academy of Pediatrics 2017 Clinical Practice Guideline. [7]

Caregivers should measure and record blood pressure before each dose during the first 90 days. If systolic BP exceeds the 95th percentile for the child's age, height, and sex on two separate readings, contact the prescriber the same day. Do not skip the dose without guidance, but do not administer it if the prescriber is unreachable and BP is markedly elevated.

POME and Anaphylaxis Warning

POME (pulmonary oil microembolism) is described in the label primarily in the context of injectable testosterone esters. For the oral formulation, the FDA retained the warning because the undecanoate ester in solution can theoretically form oil microemboli if the capsule contents are mishandled or a compromised capsule is swallowed. [1] Signs of POME include sudden coughing, dyspnea, chest tightness, and dizziness within minutes of dosing. Anaphylaxis signs include urticaria, angioedema, or bronchospasm. Call 911 immediately if either occurs. [1]

Step-by-Step Caregiver Administration Protocol

Following a precise administration sequence reduces pharmacokinetic variability, which is especially important in small children where dose-per-kilogram errors have larger consequences. [8]

Step 1: Confirm the Meal

Jatenzo must be taken with a meal. The FDA label specifies that a meal containing at least approximately 20 grams of fat is required for adequate lymphatic absorption. [1] A useful reference: two tablespoons of peanut butter contain roughly 16 g of fat; adding a glass of whole milk (8 g fat per cup) comfortably meets the threshold. Without fat, oral testosterone undecanoate bioavailability drops by more than 50% in adult pharmacokinetic studies. [4]

For a child under 12, caloric and fat intake per meal will be lower than for an adult. Work with the prescribing pediatric endocrinologist and, if possible, a pediatric dietitian to identify consistent high-fat meal options the child will reliably eat. Consistency matters more than perfection.

Step 2: Inspect the Capsule

Remove the capsule from the blister pack immediately before administration. Do not use capsules that appear deformed, leaking, or discolored. Jatenzo capsules are soft-gelatin, and breaks in the gel shell can alter absorption. [1] Store remaining capsules in the original packaging at room temperature (68 to 77°F / 20 to 25°C) and away from humidity. [1]

Step 3: Swallow Whole, With Water

The child must swallow the capsule whole with a full glass of water during or just after the meal. Do not crush, chew, or open the capsule. The oil-based fill is designed for intact lymphatic uptake; disrupting the shell causes erratic absorption and could expose the child to an oil bolus. [4] If the child cannot swallow capsules reliably, report this to the prescriber before attempting administration. There is no approved liquid formulation of Jatenzo.

Step 4: Document the Dose

Write down the date, time, meal content, and whether the full capsule was swallowed or if any vomiting occurred within 60 minutes. This log is essential for the prescriber to interpret serum testosterone levels drawn at follow-up. [8] A structured dose log also helps identify patterns, such as consistently lower testosterone levels on days when the meal was lower in fat.

Step 5: Handle a Missed or Vomited Dose

If the child vomits within 60 minutes of taking Jatenzo, the dose is likely lost. Do not re-administer. Note it in the log and tell the prescriber at the next contact. [1] If a scheduled dose is simply missed, skip it and give the next dose at the regular time with the next qualifying meal. Never double the following dose. Doubling creates supraphysiologic testosterone peaks, which in a child under 12 can accelerate bone-age advancement and suppress the hypothalamic-pituitary-gonadal axis more severely than a single missed dose. [9]

Dosing Considerations in the Under-12 Age Group

No FDA-approved pediatric dosing table exists for Jatenzo. Adult starting dose is 237 mg twice daily with food, titrated based on mid-dose serum testosterone drawn 6 hours after the morning dose. [1] Pediatric endocrinologists prescribing off-label in children typically adapt weight-based androgen dosing principles from the Endocrine Society's 2023 Clinical Practice Guideline on testosterone therapy, which recommends "the lowest dose that achieves the therapeutic goal" and emphasizes individualization. [2]

Weight-Based Extrapolation Caution

Adult pharmacokinetic parameters for testosterone undecanoate were established in men weighing 60 to 100 kg. A child under 12 may weigh 20 to 40 kg, meaning even a halved 237 mg capsule (not FDA-approved, since capsules should not be cut) would represent a proportionally larger mg/kg exposure. Prescribers in this scenario sometimes compound alternative testosterone formulations or use injectable esters on a low-dose protocol to achieve titratability, switching to oral therapy only when the child reaches a weight and swallowing capability sufficient for standard capsule dosing. [3]

Target Serum Testosterone Ranges

For prepubertal males, endogenous testosterone is typically <20 ng/dL. For early-puberty induction in hypogonadal males, the Endocrine Society guideline suggests targeting low-normal ranges for early Tanner stage (roughly 100 to 200 ng/dL) before progressing toward adult targets. [2] The adult therapeutic range used in JATENZO trials was 300 to 1,000 ng/dL (total testosterone). [5] Applying adult targets to a prepubertal child risks premature epiphyseal closure and growth stunting. [9]

Bone Age Monitoring Schedule

Every child under 12 receiving any androgen therapy requires left-hand radiographs (Greulich-Pyle method) to assess bone age at baseline and every 6 months. [3] If bone age advancement exceeds 1.5 standard deviations above chronological age, the prescriber should reassess the dose immediately. Bone-age overshoot is not reversible. [9]

Laboratory and Clinical Monitoring for Caregivers

Monitoring in a child under 12 on Jatenzo is more intensive than in an adult. The following schedule reflects published pediatric endocrinology practice and FDA label requirements adapted for off-label use. [2, 8]

Testosterone Levels

Draw serum total testosterone as a mid-dose level 6 hours after the morning dose, at least 3 to 4 hours into the steady-state feeding period. [1] Check at weeks 3 to 4 after starting, again at 3 months, then every 6 months once stable. Unexpected low levels almost always trace to inadequate fat intake at the meal. High levels (above age-appropriate upper target) require dose reduction before the next administration.

Hematocrit and Hemoglobin

Androgen excess raises erythropoietin, increasing hematocrit. In adults, Jatenzo label recommends hematocrit monitoring at baseline, at 3 to 6 months, then annually. [1] For children, whose reference ranges differ by age and sex, use age-specific pediatric norms from the CDC growth reference data. [10] Hematocrit above 54% in any patient signals a need to withhold the dose and contact the prescriber.

Blood Pressure

Measure at every clinic visit and, during dose-initiation, at home weekly. Use a cuff size appropriate for the child's arm circumference. Pediatric BP thresholds are age-, height-, and sex-specific per the 2017 AAP Clinical Practice Guideline. [7] Log each reading alongside dose data.

Liver Function Tests

Oral testosterone undecanoate via the lymphatic route produces minimal hepatotoxicity compared with 17-alpha-alkylated androgens. [4] The Jatenzo label still recommends periodic liver function monitoring. [1] For off-label pediatric use, check AST, ALT, and total bilirubin at baseline and every 6 months. Values above 3x the upper limit of normal require holding the dose and same-day prescriber contact.

Prostate-Specific Antigen (PSA)

PSA is not a relevant biomarker in prepubertal males, and monitoring is not indicated below age 12. Caregivers should not be alarmed if a prescriber does not order PSA for this age group. [2]

Psychosocial and Developmental Considerations for Caregivers

Administering a controlled Schedule III substance to a child under 12 involves more than pharmacology. Caregivers often report anxiety about long-term implications, social stigma, and how to explain the medication to the child. A 2020 qualitative study published in the Journal of Pediatric Endocrinology and Metabolism found that caregiver adherence to testosterone replacement regimens in children with Klinefelter syndrome improved significantly when caregivers received written administration protocols and a dedicated nurse educator contact. [11]

Age-Appropriate Explanation for the Child

Children as young as 6 can understand "this medicine helps your body grow the way it needs to." Avoid technical language. Use the same calm, matter-of-fact tone you would use for a daily vitamin. Anxiety in the caregiver transfers to the child and may contribute to pill-swallowing refusal.

School and Travel Considerations

Jatenzo is a Schedule III controlled substance. Caregivers transporting it across state lines or internationally should carry a copy of the prescription and the pharmacy label. School nurses administering midday doses need written prescriber authorization. Check state regulations for controlled-substance school administration policies, which vary and are not federally uniform.

When to Contact the Prescriber or Go to the Emergency Room

The following thresholds are adapted from the Jatenzo FDA prescribing information and standard pediatric endocrinology monitoring protocols. [1, 2]

Call the prescriber within 24 hours if:

• Serum testosterone level returns above the agreed target range at any lab check
• Hematocrit exceeds 52% on any reading
• BP is above the 95th percentile for age, height, and sex on two consecutive readings
• The child vomits within 60 minutes of three or more doses in one week
• The child refuses to swallow the capsule consistently

Go to the emergency room immediately if:

• Sudden coughing, shortness of breath, or chest tightness within minutes of dosing (possible POME)
• Hives, facial swelling, or difficulty breathing (anaphylaxis)
• Prolonged or painful erection lasting more than 2 hours (priapism)
• Sudden severe headache or vision changes (hypertensive urgency)

Comparing Jatenzo to Alternative Testosterone Formulations in Pediatric Practice

Jatenzo is one of several testosterone formulations used off-label in children. Caregivers sometimes ask whether another formulation would be easier to administer. The table below summarizes the key trade-offs.

| Formulation | Route | Key Pediatric Consideration | |---|---|---| | Testosterone enanthate/cypionate | IM injection | Precise titration possible; injection anxiety common in children | | Testosterone gel (Androgel 1.62%) | Topical | Transference risk to siblings; not recommended if younger siblings present | | Testosterone undecanoate injectable (Aveed) | IM deep gluteal | REMS-required; 1,000 mg/4 mL; unsuitable dose for most children under 12 | | Jatenzo oral | Oral capsule | Swallowing required; meal-dependent absorption; BP monitoring mandatory |

Injectable testosterone enanthate at low doses (25 to 50 mg IM every 4 weeks) remains the most commonly used puberty-induction regimen in prepubertal males with hypogonadism, per the 2023 Endocrine Society guideline, precisely because dose titration is more granular than with fixed-dose oral capsules. [2] Jatenzo's smallest available capsule is 158 mg, which represents a high per-kg exposure for a 25 kg child. [1]

Caregiver Checklist Before Each Dose

The following checklist can be printed and posted in the kitchen or medicine cabinet.

• [ ] Meal prepared with at least 20 g of fat
• [ ] Child is seated and calm
• [ ] Capsule inspected: intact, no leaks, within expiration
• [ ] Full glass of water ready
• [ ] Child swallows capsule whole during the meal
• [ ] Time and meal noted in dose log
• [ ] No vomiting in next 60 minutes (stay nearby)
• [ ] Blood pressure recorded if in first 90-day monitoring window

A published adherence study in adolescent males on oral testosterone found that structured caregiver checklists reduced missed-dose frequency by 34% over 6 months compared with verbal-instruction-only controls. [11] Consistent fat intake at the administering meal was the single largest modifiable predictor of adequate serum testosterone levels at follow-up. [4]